Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health...(p Due to its chronic nature and the need...)

Date:5/7/2008

p>"Due to its chronic nature and the need for frequent hospitalization, schizophrenia is associated with significant economic burden," said Dr. Philip Janicak, Professor of Psychiatry, Rush University Medical Center and one of the lead investigators in the trial.(b) "Treating physicians, patients and their families would welcome treatment options that may help reduce resource use."

"We should keep in mind, important study limitations include the lack of a control group; pre/post design comparing historical data with data collected in the trials could create a bias due to the mismatch in settings; and patients may have had more frequent contact with treating physicians and investigators during the trial period which could favor the outcomes in the open-label phase. Therefore prospective studies should be conducted to confirm these findings," Dr. Janicak said.

A separate post-hoc analysis from those same three OLE studies also presented today examined employment status of patients with schizophrenia treated with paliperidone ER over the 52-week OLE period. A total of 1,012 patients 18 years and older with a diagnosis of schizophrenia were included. At their first and last visits, patients were placed into nine different occupational status categories.

The percentage of patients who reported employment during the open-label phase of the study increased throughout the 52-week study period. The number of patients who were employed full-time at their last visit almost doubled from 4.8 percent at the first visit to 8.8 percent, and the number of patients in any form of employment (including students, but excluding housewives or those retired) increased by 10.6 percent.

The studies were sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. markets paliperidone ER in the U.S.

Paliperidone ER, an atypical antipsychotic medication, was first approved in the U.S. in December
'/>"/>

SOURCE Johnson & Johnson Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related biology technology :

1. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
2. Nucletron Announces Oncentra(R) Brachy* Treatment Planning Solution for Multimodality Environment
3. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
4. PEAT International Commissions Plasma-Based Waste Treatment Facility Designed Specifically for Onsite Waste Processing
5. Quest PharmaTech Receives Support from National Research Councils Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
8. Biotherm Announces a Unique Dermobiotic Three-Step Anti-Cellulite Slimming Treatment
9. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
10. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
11. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain